Stilamin IV Injection or Infusion

Introduction

Stilamin IV Injection or Infusion 3 mg/ampoule is a peptide hormone that inhibits the release of several other hormones and digestive enzymes. It is used in medical practice to manage conditions involving excessive hormone secretion and certain types of cancer. It is also used in diagnostic testing and research.

Uses

Stilamin IV Injection or Infusion 3 mg/ampoule is used to treat:

Acromegaly (excess growth hormone secretion)
Neuroendocrine tumors (such as pancreatic tumors and carcinoid syndrome)
Gastrointestinal bleeding (to reduce blood flow and secretion)
Diagnostic imaging of neuroendocrine tumors

Brand Name	Stilamin
Type	IV Injection or Infusion
Weight	3 mg/ampoule
Generic	Somatostatin
Manufacturer	Janata Traders (Mfg. by: Merck)
Available in	English বাংলা

Mechanism of Action

Stilamin IV Injection or Infusion 3 mg/ampoule exerts its effects by binding to specific somatostatin receptors on cell surfaces. This binding inhibits the release of growth hormone from the pituitary gland, reduces the secretion of insulin and glucagon from the pancreas, and decreases the release of gastrointestinal hormones and digestive enzymes. Its broad inhibitory action impacts various physiological processes.

How Long Does It Take to Work?

The effects of somatostatin can be seen within a few hours to days after administration, depending on the condition being treated. For acute conditions like gastrointestinal bleeding, effects may be observed more quickly. For chronic conditions like acromegaly, it may take several weeks to achieve optimal control.

Absorption

Stilamin IV Injection or Infusion 3 mg/ampoule is not well absorbed from the gastrointestinal tract and is typically administered parenterally (subcutaneously or intravenously) to ensure efficacy. When used in its synthetic form, it bypasses the digestive system to reach systemic circulation directly.

Route of Elimination

Stilamin IV Injection or Infusion 3 mg/ampoule is metabolized primarily by the liver and kidneys. It is broken down into inactive metabolites that are then excreted in the urine.

Dosage

Somatostatin is given intravenously, by slow bolus injection (3 to 5 minutes) of 250 µg or by continuous infusion at a rate of 250 µg/hour (equivalent of approximately 3.5 µg/kg body weight/hour). The lyophilised powder should be reconstituted with the physiological sodium chloride solution immediately prior to use. For continuous infusion one 3 mg of Somatostatin ampoule should be used to prepare a 12 hours infusion. The solution may be either saline or 5 % dextrose and should be adjusted to guarantee an outflow of 250 µg somatostatin/hour. The use of a perfusion syringe is recommended.

Treatment of severe acute bleeding from the upper gastro-intestinal tract, including from oesophageal varices: It is recommended to start by a slow intravenous injection of 250 µg of Somatostatin as loading dose, then immediately followed by an intravenous infusion at a rate of 250 µg/h. In case of interruption of more than 3 to 5 minutes between two infusions, an additional slow intravenous injection of 250 µg is recommended to ensure a continuous treatment. Once the haemorrhage has stopped (usually in less than 12 to 24 hours), treatment should be continued for 48-72 hours in order to avoid rebleeding. Treatment up to 120 hours has been routinely performed in this indication.

Adjuvant treatment in pancreatic, biliary and intestinal fistulae: A continuous infusion of Somatostatin at a rate of 250 µg/h is recommended until closure of the fistulae (2-20 days). This infusion should be performed in addition to total parenteral nutrition. Once the fistula has been closed, treatment should be continued for 1 to 3 days and stopped progressively in order to avoid rebound effect. Prophylactic treatment of postoperative complications following pancreatic surgery: Somatostatin is administered at the beginning of the surgical intervention at a rate of 250 µg/h and treatment is continued for 5 days.

The dosage of somatostatin varies depending on the condition being treated:

For acromegaly: 100-250 micrograms administered subcutaneously 2-3 times daily.
For neuroendocrine tumors: 250-500 micrograms administered subcutaneously 2-3 times daily or as prescribed by a physician.
For gastrointestinal bleeding: Continuous intravenous infusion, with dosing adjusted based on clinical response.

Administration

Stilamin IV Injection or Infusion 3 mg/ampoule is typically administered via subcutaneous injection for chronic conditions or as an intravenous infusion for acute conditions. Dosage and frequency are tailored to the patient's needs and response.

Side Effects

Common side effects include:

Nausea
Diarrhea
Injection site reactions (pain, redness, or swelling)
Fatigue

Serious side effects may include:

Hypoglycemia
Bradycardia (slow heart rate)
Hypothyroidism

Toxicity

Acute toxicity from somatostatin is rare but may include symptoms like severe hypoglycemia or bradycardia. Chronic high doses can lead to issues such as hypothyroidism and potential impacts on glucose metabolism.

Precautions

Precautions include:

Monitoring blood glucose levels, especially in diabetic patients
Regular thyroid function tests, as somatostatin can affect thyroid hormone levels
Monitoring heart rate, as bradycardia can occur

Interaction

Stilamin IV Injection or Infusion 3 mg/ampoule may interact with:

Insulin or oral hypoglycemic agents, as it can alter glucose metabolism
Thyroid hormone replacement therapy, as it can affect thyroid function
Other medications affecting heart rate or rhythm

Disease Interaction

Use somatostatin cautiously in patients with:

Diabetes or glucose intolerance
Thyroid disorders
Cardiac conditions

Drug Interaction

Stilamin IV Injection or Infusion 3 mg/ampoule may interact with:

Medications that affect glucose levels, potentially requiring dose adjustments
Drugs that affect cardiac rhythm, due to potential bradycardia

Food Interactions

There are no specific food interactions with somatostatin. However, maintaining a balanced diet and monitoring blood glucose levels are advisable for patients with diabetes.

Pregnancy Use

Stilamin IV Injection or Infusion 3 mg/ampoule should be used during pregnancy only if clearly needed, as its safety profile in pregnant women is not well established. Risk-benefit assessment is required before use.

Lactation Use

The use of somatostatin during lactation is not well studied. It is advisable to use it with caution and consult with a healthcare provider regarding its use while breastfeeding.

Acute Overdose

In case of an acute overdose, symptoms may include severe bradycardia, hypoglycemia, or gastrointestinal disturbances. Treatment is supportive, focusing on symptom management and monitoring vital signs.

Contraindication

Stilamin IV Injection or Infusion 3 mg/ampoule is contraindicated in:

Patients with hypersensitivity to somatostatin or its analogs
Severe liver dysfunction

Use Direction

Stilamin IV Injection or Infusion 3 mg/ampoule should be administered according to the prescribed dosage and frequency. It is important to follow the healthcare provider's instructions and monitor for any adverse effects.

Storage Conditions

Stilamin IV Injection or Infusion 3 mg/ampoule should be stored in the refrigerator at 2-8°C (36-46°F) and protected from light. It should be kept in its original packaging and out of reach of children.

Volume of Distribution

The volume of distribution of somatostatin is approximately 0.1-0.2 L/kg, indicating that it is distributed primarily in the extracellular fluid and tissues.

Half Life

The half-life of somatostatin is approximately 1-2 minutes in plasma, but its effects may last longer due to its action on hormone release and physiological processes.

Clearance

Stilamin IV Injection or Infusion 3 mg/ampoule is cleared from the body primarily by the liver and kidneys. Its clearance rate can be influenced by hepatic and renal function.

See in details version Stilamin IV Injection or Infusion 3 mg/ampoule also Stilamin IV Injection or Infusion 3 mg/ampoule in bangla